Theophylline ( DrugBank: Theophylline )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
236	偽性副甲状腺機能低下症	5
299	嚢胞性線維症	2

236. 偽性副甲状腺機能低下症

---

臨床試験数 : 6 /  薬物数 : 4 - (DrugBank : 2) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 28

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04551170 (ClinicalTrials.gov)	July 13, 2020	9/9/2020	Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism	Pseudohypoparathyroidism;Albright Hereditary Osteodystrophy;Pseudohypoparathyroidism Type 1a	Drug: Theophylline;Drug: Placebo	Vanderbilt University Medical Center	NULL	Recruiting	2 Years	12 Years	All	34	Phase 2	United States
2	NCT04240821 (ClinicalTrials.gov)	May 22, 2020	21/1/2020	Theophylline for Treatment of Pseudohypoparathyroidism	Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism	Pseudohypoparathyroidism;Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy	Drug: Theophylline ER	Ashley Shoemaker	NULL	Enrolling by invitation	2 Years	99 Years	All	34	Phase 2	United States
3	NCT03718403 (ClinicalTrials.gov)	April 10, 2019	8/9/2017	Effect of Theophylline in Pseudohypoparathyroidism	Effect of Theophylline in Pseudohypoparathyroidism	PHP Ia;PHP IB;Php1C	Drug: Theophylline	Massachusetts General Hospital	NULL	Not yet recruiting	5 Years	21 Years	All	40	Phase 4	NULL
4	NCT03029429 (ClinicalTrials.gov)	September 1, 2018	18/1/2017	Theophylline Treatment for Pseudohypoparathyroidism	Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism	Pseudohypoparathyroidism;Albright Hereditary Osteodystrophy	Drug: Theophylline;Drug: Placebos	Vanderbilt University Medical Center	Harvard University	Recruiting	13 Years	99 Years	All	34	Phase 2	United States
5	NCT02463409 (ClinicalTrials.gov)	June 2015	20/5/2015	Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)	Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a	Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy	Drug: Theophylline	Vanderbilt University Medical Center	Massachusetts General Hospital	Completed	10 Years	21 Years	All	6	Phase 2	United States

先頭へ

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01684683 (ClinicalTrials.gov)	November 2012	11/9/2012	The Effect of Theophylline in the Treatment of Bronchiectasis	Clinical Efficacy and Safety of Theophylline in the Treatment of Non-Cystic Fibrosis(NCF) Bronchiectasis	Bronchiectasis	Drug: Theophylline;Drug: Placebo(for Theophylline)	The First Affiliated Hospital of Guangzhou Medical University	NULL	Completed	18 Years	70 Years	Both	100	Phase 4	China
2	ChiCTR-TRC-12002470	2012-09-15	2012-08-02	The effect of theophylline in the treatment of bronchiectasis, a random, double blind study	The effect of theophylline in the treatment of bronchiectasis, a random, double blind study.	bronchiectasis not due to cystic fibrosis	1:theophylline;2:theophylline;	The first affiliated hospital of Guangzhou Medical University	NULL	Completed	15	65	Both	1:46;2:46;		China

先頭へ